London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Morning Guys, nice to see a bit of blue sky here in London this morning.
Bermuda/Guys, does anyone have a link to the above event?? Unfortunately I missed it during the week.
Looking forward to the end of half year report H1 2020 too, so difficult to form any real opinions at the moment, and it is harder still calling any trades either!!!
Saying that pretty sure we have a decent buy from yesterday to come, lets hope there are a few, to a positive day all, hoping our seller has gone away on a nice long weekend!!
I hope that anyone watching was able to put thoughts of Scancell to one side, look beyond and make a balanced, objective judgement. The purpose of the session was fact finding - to help with planning and understanding what the Country may be facing over the coming months. It was inevitable that they would focus on the Oxford vaccine as it will be the first in the world to complete phase III trials and therefore potentially the first available vaccine. Kate Bingham mentioned several times that they had a portfolio of other vaccines for future development.
On a really serious note, if you don't get a chance to watch, one issue that was raised was the possibility of a combination of a COVID-19 spike and a bad flu season so please make sure you get your flu jab this year.
Presumably she only knows her stuff if she authorises a blank cheque to Scancell!?
Will try and catch up over the weekend, I guess I am split by two very different perspectives, one how the world finds a vaccine to rid us of the COVID Virus threat, and two will there be any role Scancell can play in it.
On the first one I have two growing fears, being a second wave of the virus, bing predicted by more and more scientists and having ventured out just a few times recently can see quite clearly where the fears are eminating from.
Will let you know more when iget to catch up with.
I'm not sure whether it's still available. If so, perhaps give it a go. You may come away feeling a little reassured that a massive effort is being put into finding, manufacturing and delivering therapies and vaccines for the whole of the UK. Kate Bingham (Chair of Vaccines Taskforce) came across as a lady at the top of her game and certainly knows her stuff.
Unfortunately not just reading the comments made during and after
Did you watch the session?
I think you mean Prof. John Bell .............. from Oxford university
Thamks WTP, yeah read a few of your posts yesterday, find the whole thing so hard to justify.
Hopefully we will get the end of H1 Update for 2020 tomorrow possible, find it hard to see where we go next, and I wonder what info they can give us about trials which are still not confirmed can take place yet.
Well should make for an interesting update, careful what you wish for, but yeah understand where you are coming from.
GN, catch you guys tomorrow, I hope.
HI @c7, I was trying to stay away from the topic of the Parliamentary Science & Tech Committee as it gets me too wound up! But we posted about this yesterday and to uses Inans words (i paraphrase):
"Nothing but advertising, showboating, congratulating themselves for their "amazing acheivement"... Labours Dawn Butler most pertinent question was challenging the GOV Advisors .. on "language"!
Basically as far as i know no real mention of funding(?), Sir John(?), the Canadian guy was the only impartial one their saying betting on just two vaccines was a risk and talked about importance of T-cells, but on both oocasaions the coversation wasn't reciprocated/came to an abrupt end.
As far as i could tell no one questioned about other projects or how Oxford/imperial was validated/selected/panel reviewd or more importanty how it was funded. It was IMO just a big indulgent back slapping session, almost solely focused on Oxford and it's production. I'm fairly sure other vaccines/projects weren't even properly mentioned? @LL may know better.
But can anyone tell me if the government/UKRI have providedn funding to other projects outside of Oxford/Imperial yet? I have a feeling there was a small list (i.e. edinburgh uni) but the amounts were piffling in comparison.
Is this what you mean inan?
Presumably the thymus deletes high avidity TCells because there is a danger of attacking "self".
But there is no restriction when it comes to activation by dendritic cells.
I see our mate Mellman is getting in on the act.
Hi Inanaco, how did that meet finish. Are they still considering vaccine alternatives or just justifying grants to Imperial College and Oxford?
tried to explain this before, immunobody generates what the body deletes .... high Avidity ... are potent t cells
Two important observations arose from this study. First of all, T cell recognition in the thymus resulted in deletion of cells bearing high-affinity TCR. Importantly, however, deletion of cells by recognition of antigen in the periphery appeared to be equally effective. This then argues against the idea that T cells are more sensitive to central or thymic mechanisms of deletion than they are to similar mechanisms in the periphery. We must now question whether immature cells are inherently more sensitive to cell deletion in vivo or whether it is the relative amount of antigen expressed that dictates the balance between central and peripheral tolerance. Further work will be required to define the amount of antigen exposure, in terms of functional MHC-peptide complexes on antigen-presenting cells (APC), required for central versus peripheral tolerance in vivo. Given this, it will be possible to categorically say whether mature lymphocytes are equally or less sensitive to deletion than their immature counterparts.
lol ....... i know what to look for ........ RRR
research research and ... try and understand it ..
Not only are you thinking like Lindy Durrant, you're writing like her too! :)
Tolerance induction by thymic epithelium induces a state of so-called "split tolerance," characterized in vivo by tolerance and in vitro by reactivity to a given thymically expressed antigen. Using a model major histocompatibility complex class I antigen, H-2Kb (Kb), three mechanisms of thymic epithelium-induced tolerance were tested: induction of tolerance of tissue-specific antigens exclusively, selective inactivation of T helper cell-independent cytotoxic T lymphocytes, and deletion of high-avidity T cells. To this end, thymic anlagen from Kb-transgenic embryonic day 10 mouse embryos, taken before colonization by cells of hemopoietic origin, were grafted to nude mice. Tolerance by thymic epithelium was not tissue-specific, since Kb-bearing skin and spleen grafts were maintained indefinitely. Only strong priming in vivo could partially overcome the tolerant state and induce rejection of some skin grafts overexpressing transgenic Kb. Furthermore, the hypothesis that thymic epithelium selectively inactivates those T cells that reject skin grafts in a T helper-independent fashion could not be supported. Thus, when T-cell help was provided by a second skin graft bearing an additional major histocompatibility complex class II disparity, tolerance to the Kb skin graft was not broken. Finally, direct evidence could be obtained for the avidity model of thymic epithelium-induced negative selection, using Kb-specific T-cell receptor (TCR) transgenic mice. Thymic epithelium-grafted TCR transgenic mice showed a selective deletion of those CD8+ T cells with the highest density of the clonotypic TCR. These cells presumably represent the T cells with the highest avidity for Kb. We conclude that split tolerance induced by thymic epithelium was mediated by the deletion of those CD8+ T lymphocytes that have the highest avidity for antigen.
He knew you would say that!
'i know exactly what lindy is thinking'
I read some farcical claims on bulletin boards but had never come across a claim to have the power of mind reading before.
Congratulations on your super power.
I will have a look when I have time.
something of interest for you Ray to research ... if you are interested
CD4 T cells can activate .......... innate cells such as macrophages and NK cells to contribute to anti-tumour responses
Lindy obviously knows this, but they have not looked for it in the pre-clinical work of moditope
if you have time concentrate on the NK cells ... and why are they are of interest to current vaccine designers
hint ... loss of antigen ...
Ah ok, so you meant too potent
Grammar slips can cause confusion
or worse .. CRS ...